# CheckMate 9LA (NCT03215706)

> A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03215706
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Ipilimumab; Nivolumab; Carboplatin; Paclitaxel; Pemetrexed; Cisplatin
- Enrollment: 719
- Primary outcome: Overall Survival (OS)

## Commentary we found

- Podcasts: 45
- YouTube: 40
- X threads: 26

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-9la-nct03215706

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03215706", "email": "<work email>"}; the inbox owner confirms by the emailed link.